"Impact of age on markers of HIV-1 disease"
Pirrone V, Libon DJ, Sell C, Lerner CA, Nonnemacher MR, and B Wigdahl
Future Virology, 9(1):81-101, 2013.
"Substance abuse, HIV-1 and Hepatitis"
Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, and B Wigdahl
Current HIV Research, 10(7): 557-571, 2012.
"Impact of Tat genetic variation on HIV-1 disease"
Li L, Dahiya S, Kortagere S, Cunningham D, Pirrone V, Nonnemacher MR, and B Wigdahl
Advances in Virology: 123605, 2012.
"Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors"
McFadden K, Fletcher P, Rossi F, Kantharaju F, Umashankara M, Pirrone V, Rajagopal S, Gopi H, Krebs FC, Martin-Garcia J, Shattock R, and I Chaiken
Antimicrobial Agents and Chemotherapy, 56(2): 1073-1080, 2012.
"Application and Removal of Polyanionic Microbicide Compounds Enhances Subsequent Infection by HIV-1"
Pirrone V, Passic SR, Wigdahl B, and FC Krebs
Virology Journal, 9: 33, 2012.
"Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis"
Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, and MR Nonnemacher
J. Neurovirol., 17(4): 291-302, 2011.
"Breaking the barrier: the effects of HIV-1 on the blood brain barrier"
Strazza M, Pirrone V, Wigdahl B, and MR Nonnemacher
Brain Research, 1399: 96-115, 2011.
"The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1"
Pirrone V, Wigdahl B, and FC Krebs
Antiviral Research, 90(3): 168-182, 2011.
"Combinatorial approaches to the prevention and treatment of HIV-1 infection"
Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, and FC Krebs
Antimicrobial Agents and Chemotherapy, 55(5): 1831-1842, 2011.
"Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment"
Li L, Aiamkitsumrit B, Pirrone V, Nonnemacher MR, Wojno A, Passic S, Flaig K, Kilareski E, Blakey B, Ku J, Parikh N, Shah R, Martin-Garcia J, Moldover B, Servance L, Downie D, Lewis S, Jacobson JM, Kolson D, and B Wigdahl
J. Neurovirol., 17(1): 92-109, 2011.
"A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection"
Pirrone V, Miller SR, Schlipf L, Ferguson ML, Kish-Catalone TM, Wigdahl B, Rando R, Labib ML, and FC Krebs
J. Biomed. Biotechnol., 2010: 548749, 2010.
"Innate and Adaptive Factors Regulating Human Immunodeficiency Virus Type 1 Genomic Activation"
Shah S, Nonnemacher MR, Pirrone V, and B Wigdahl
J Neuroimmune Pharmacol., 5(3): 278-293, 2010.
"Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection"
Thakkar N, Pirrone V, Schlipf L, Ferguson ML, Miller SR, Wigdahl B, Labib ML, Rando R, and FC Krebs
Antimicrobial Agents and Chemotherapy, 54(5): 1965-1972, 2010.
"Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection"
Thakkar N, Pirrone V, Schlipf L, Ferguson ML, Miller SR, Wigdahl B, Labib ML, Rando, R, and FC Krebs
Antimicrobial Agents and Chemotherapy, 53(2): 631-638, 2009.
"Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120"
Gopi HN, Cocklin S, Pirrone V, McFadden K, Baxter S, Tuzer F, Zentner I, Krebs FC, and I Chaiken
Journal of Molecular Recognition, Special Issue, March 2008.